Objective: Meigs' syndrome presenting as an ovarian tumor with elevated serum cancer antigen 125 (CA 125) levels is unusual. Only 37 cases have been reported, including three cases of ovarian sclerosing stromal tumor (SCT). Many reports have suggested that the presence of ascites is the major factor inducing mesothelial expression of CA 125. Case Report: An 18-year-old woman presented with massive ascites, elevated serum CA 125 levels, and radiographic evidence of ovarian tumor. The histological and immunohistochemical examinations revealed a benign SCT. Conclusion: SCT is a benign ovarian tumor and complete excision is curative. We also review all 37 cases and discuss possible mechanisms of Meigs' syndrome and elevated serum CA 125 level.
(alpha fetoprotein: 1.17 ng/mL; carcinoembryonic antigen: 0.7 ng/mL; and cancer antigen 19-9: 22.86 U/mL) were within normal limits. Large-volume paracentesis procured 9,000 mL of clear yellow transudate. Cytologic analysis of ascitic fluid was negative for malignant cells. Exploratory laparotomy revealed a large right ovarian tumor with a smooth surface without intrabdominal carcinomatosis. Intraoperative examination of frozen sections of the right ovarian tumor demonstrated a benign stromal tumor, and a right salpingo-oophorectomy was performed. On gross examination, the specimen consisted of a 890-g ovarian tumor measuring 14.5 cm Â 13 cm Â 9.5 cm attached to an unremarkable fallopian tube. The external surface was grayish white and glistening. The solid-cystic tumor was yellow, white, and solidly firm, with areas of myxoid and cystic change (Fig. 3A) . No necrosis was present. Microscopically, the ovarian tumor was composed of a pseudolobular arrangement of tumor cells with alternating hypercellular and hypocellular areas (Fig. 3B) . The tumor cells were spindle to polygonal in shape with eosinophilic to vacuolated cytoplasms, bland nuclei, and low levels of mitotic activity (Fig. 3C) . Hemangiopericytomalike vessels, myxoid to fibrotic stroma, and focal cystic change were noted. The tumor was immunopositive for a-inhibin (Fig. 3D ) and immunonegative for CA 125 and cytokeratin. The pathologic diagnosis was a sclerosing stromal tumor (SST).
The postoperative course was uneventful; the serum CA 125 level returned to normal and the ascites resolved.
Discussion
In 1989, Jones and Surwit [1] reported on a patient with Meigs' syndrome associated with fibroma-thecoma of the ovary and elevated CA 125 levels. Since then, 37 cases have been reported [1e26], including three with SSTs (Table 1) . Herein, we report on the fourth known case of Meigs' syndrome associated with SST of the ovary.
SSTs account for only 2.5% of ovarian sex cord-stromal tumors. Unlike other sex-cord stromal tumors, which typically develop in the fifth and sixth decades of life, SSTs often present in the second and third decades of life and approximately 80% of cases present in patients younger than 30 years. Most cases of SST are benign and unilaterally right sided. No cases of recurrent disease after complete excision have been reported.
In 1937, Meigs and Cass [27] published a report on seven patients presenting with a triad of findings: ovarian tumor, pleural effusion, and ascites characterized by resolution of symptoms with removal of the tumor. In 1954, Meigs [28] proposed that the classification of Meigs' syndrome be restricted to benign and solid ovarian tumors with the gross appearance of a fibroma (fibroma, thecoma, granular cell tumor, or benign Brenner tumor) in patients with nonmalignant ascites or/and hydrothorax that resolves after removal of the tumor. When other ovarian tumors (metastatic or primary malignant tumors or uterine or fallopian tube tumors) are found in association with the criteria of Meigs' syndrome, the term pseudo-Meigs' syndrome is used.
The mechanisms by which peritoneal and pleural effusion develop in both Meigs' and pseudo-Meigs' syndromes are not fully understood. Meigs and Cass [27] suggested that irritation of the peritoneal surface by a hard, solid ovarian tumor or leakage from the edematous stroma of a tumor could stimulate the production of peritoneal fluid. Other possible mechanisms described by other investigators include active fluid secretion by the tumor, obstruction or congestion of peritoneal lymphatics and veins by the tumor [12] , and increased permeability of the neovasculature and transudation through the tumor surface that exceeds the capacity for reabsorption. More recently, reports have suggested that the mesothelium is the main factor in the production of ascites [7] .
CA 125, identified in 1981 by Bast et al [29] , is an antigenic determinant of a highemolecular weight glycoprotein and is now the most widely studied serum biomarker for ovarian tumors. Although as many as 50% of Stage I and more than 90% of advanced-stage ovarian cancers are associated with an elevated serum level of CA 125, the specificity of the CA 125 determinant is low, as increased levels have also been found in cases of adenocarcinoma of the endocervix, endometrium, and fallopian tube; nongynecological malignancy (e.g. pancreas, colorectum, breast, lung, and liver); multiple benign diseases; and conditions, such as endometriosis, uterine myoma, pelvic inflammatory disease, early pregnancy, ascites, liver cirrhosis, heart failure, and inflammation of the pleura and peritoneum [30] .
The precise mechanism of serum CA 125 level elevation is still unclear. Some tumors express CA 125, which is absorbed into the circulation resulting in elevated serum levels. Insult to or inflammation of the peritoneum or pleura have been observed to give rise to elevated serum CA 125 levels, possibly through the stimulation of mesothelial cells to produce CA 125. Increased intrabdominal pressure caused by tumor growth may also elicit mesothelial expression of CA 125 [9] . In our review of the 37 reported cases of Meigs' syndrome with elevated serum CA 125 levels in which immunohistochemical staining of the tumor for CA 125 was performed, we found that none of the tumor specimens were positive for that determinant. Immunohistochemical analysis revealed that CA 125 was expressed at the peritoneal and omental surface, rather than in the tumor bed, in most cases [7, 9, 16] . Therefore, mesothelial expression of CA 125, rather than expression by the tumor itself, may be a major factor resulting in elevation of serum CA 125 levels in patients with Meigs' syndrome.
Ascites and pleural effusion have also been found to be correlated with elevated serum CA 125 levels. In a study of patients undergoing chronic hemodialysis, serum CA 125 levels were significantly higher in patients with the presence of serosal fluid than in patients without the presence of serosal fluid [31] . Zuckerman et al [32] also noted that in liver cirrhotic patients with ascites, elevated serum CA 125 levels were correlated with ascitic volume, and rapid decline in this marker was observed after large-volume paracentesis. Reports of CA 125 assessment in patients with benign stromal tumors without ascites describe levels lower than 35 U/mL; however, in patients with ascites, the CA 125 levels are much higher (range 500e5,000 U/mL) [33] . Mezger et al [34] found a significant linear correlation between volume of effusion and serum CA 125 values in both benign and malignant diseases, including some tumor types not known to produce the antigen. Patsner [14] also described a correlation between CA 125 elevation and volume of ascites in patients with Meigs' syndrome. After reviewing the 25 of the 37 cases of Meigs' syndrome with elevated serum CA 125 levels in which ascitic fluid volumes were reported, we found that the volume of ascites was positively correlated with higher levels of CA 125 (mean 1,577 U/mL vs. 337 U/mL when using 1,000 mL as the cutoff point), but that tumor size was not linearly associated with CA 125 values. With the exception of one case of Meigs' syndrome with underlying systemic lupus erythematosus, peritoneal or pleural effusion was the only factor contributing to the elevated CA 125 levels in the reported cases. That evidence indicates that effusion is also a major factor influencing serum CA 125 level. In conclusion, although elevation of serum CA 125 in association with a solid pelvic mass and ascites is suggestive of an ovarian malignancy, SST of the ovary associated with Meigs' syndrome is also a diagnostic possibility, especially in young patients. The mechanism by which effusion develops in Meigs' syndrome is not fully understood. In Meigs' syndrome, the elevation of serum CA 125 levels may result from mesothelial expression rather than tumor expression of that tumor marker. The presence of ascites is a major factor contributing to mesothelial expression of CA 125, and expression level is correlated with ascites volume.
